Cargando…

APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans

Since the identification of APOBEC3G (A3G) as a potent restriction factor of HIV-1, a tremendous amount of effort has led to a broadened understanding of both A3G and the APOBEC3 (A3) family to which it belongs. In spite of the fine-tuned viral counterattack to A3 activity, in the form of the HIV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheehy, Ann M., Erthal, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375093/
https://www.ncbi.nlm.nih.gov/pubmed/22720156
http://dx.doi.org/10.1155/2012/974924
_version_ 1782235713474920448
author Sheehy, Ann M.
Erthal, Julie
author_facet Sheehy, Ann M.
Erthal, Julie
author_sort Sheehy, Ann M.
collection PubMed
description Since the identification of APOBEC3G (A3G) as a potent restriction factor of HIV-1, a tremendous amount of effort has led to a broadened understanding of both A3G and the APOBEC3 (A3) family to which it belongs. In spite of the fine-tuned viral counterattack to A3 activity, in the form of the HIV-1 Vif protein, enthusiasm for leveraging the Vif : A3G axis as a point of clinical intervention remains high. In an impressive explosion of information over the last decade, additional A3 family members have been identified as antiviral proteins, mechanistic details of the restrictive capacity of these proteins have been elucidated, structure-function studies have revealed important molecular details of the Vif : A3G interaction, and clinical cohorts have been scrutinized for correlations between A3 expression and function and viral pathogenesis. In the last year, novel and unexpected findings regarding the role of A3G in immunity have refocused efforts on exploring the potential of harnessing the natural power of this immune defense. These most recent reports allude to functions of the A3 proteins that extend beyond their well-characterized designation as restriction factors. The emerging story implicates the A3 family as not only defense proteins, but also as participants in the broader innate immune response.
format Online
Article
Text
id pubmed-3375093
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33750932012-06-20 APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans Sheehy, Ann M. Erthal, Julie Mol Biol Int Review Article Since the identification of APOBEC3G (A3G) as a potent restriction factor of HIV-1, a tremendous amount of effort has led to a broadened understanding of both A3G and the APOBEC3 (A3) family to which it belongs. In spite of the fine-tuned viral counterattack to A3 activity, in the form of the HIV-1 Vif protein, enthusiasm for leveraging the Vif : A3G axis as a point of clinical intervention remains high. In an impressive explosion of information over the last decade, additional A3 family members have been identified as antiviral proteins, mechanistic details of the restrictive capacity of these proteins have been elucidated, structure-function studies have revealed important molecular details of the Vif : A3G interaction, and clinical cohorts have been scrutinized for correlations between A3 expression and function and viral pathogenesis. In the last year, novel and unexpected findings regarding the role of A3G in immunity have refocused efforts on exploring the potential of harnessing the natural power of this immune defense. These most recent reports allude to functions of the A3 proteins that extend beyond their well-characterized designation as restriction factors. The emerging story implicates the A3 family as not only defense proteins, but also as participants in the broader innate immune response. Hindawi Publishing Corporation 2012 2012-06-06 /pmc/articles/PMC3375093/ /pubmed/22720156 http://dx.doi.org/10.1155/2012/974924 Text en Copyright © 2012 A. M. Sheehy and J. Erthal. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sheehy, Ann M.
Erthal, Julie
APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title_full APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title_fullStr APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title_full_unstemmed APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title_short APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans
title_sort apobec3 versus retroviruses, immunity versus invasion: clash of the titans
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375093/
https://www.ncbi.nlm.nih.gov/pubmed/22720156
http://dx.doi.org/10.1155/2012/974924
work_keys_str_mv AT sheehyannm apobec3versusretrovirusesimmunityversusinvasionclashofthetitans
AT erthaljulie apobec3versusretrovirusesimmunityversusinvasionclashofthetitans